COX/5-LO-IN-2 

COX/5-LO-IN-2 is a COX2, EGFR, COX1, 5-LOX, BRAF and FAK inhibitor with IC₅₀ of 1.22 μM, 2.5 μM, 2.95 μM, 4.65 μM, 7.4 μM, 12.2 μM, respectively. COX/5-LO-IN-2 induces cell growth arrest at G2/M phase. COX/5-LO-IN-2 triggers apoptotic activity by up-regulating proapoptotic proteins p53, Bax, and caspase-7 and down-regulating anti-apoptotic protein Bcl-2. COX/5-LO-IN-2 can be used for the research of breast cancer^[1].

COX/5-LO-IN-2 (AS-14) (48 h) potently inhibits proliferation of PaCa-2, A-549, MCF-7, PC-3, and HT-29 human cancer cell lines with IC₅₀ values ranging from 6.92 μM to 16.02 μM^[1].
COX/5-LO-IN-2 inhibits recombinant human FAK, EGFR enzyme and BRAF^V600E kinase with IC₅₀ values of 12.2 μM, 2.5 μM, and 7.4 μM, respectively^[1].
COX/5-LO-IN-2 induces G2/M phase cell cycle arrest in MCF-7 breast cancer cells at its IC₅₀ dose of 10.27 μM^[1].
COX/5-LO-IN-2 significantly induces apoptosis in MCF-7 breast cancer cells^[1].
COX/5-LO-IN-2 up-regulates proapoptotic p53, Bax, and caspase-7 and down-regulates anti-apoptotic Bcl-2 in MCF-7 breast cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

473.50

C₂₄H₁₉N₅O₄S

O=S(C1=CC=C(N2N=C(C3=NN=C(C4=CC=C(OC)C=C4)O3)C=C2C5=CC=CC=C5)C=C1)(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abdelgawad MA, et al. In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors. Sci Rep. 2025;16(1):1973. Published 2025 Dec 23.  [Content Brief]